Leaving the European Union without an agreement would create extra costs for pharmaceutical companies and potentially disrupt vital research, the UK drug regulator has warned.
In a consultation paper on the impact of a no-deal Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) said that companies planning to sell drugs in both the EU and the UK would face extra costs, as medicines would have to be approved by regulatory agencies in both territories.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.